A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia

NCT00650871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Sleep Initiation and Maintenance Disorders

Interventions

DRUG: GW679769
DRUG: Placebo

Sponsor

GlaxoSmithKline